Stephanie Born

Q: What is Stephanie Born email address?

Email Stephanie Born at stephanie_born@merck.com. This email is the most updated Stephanie Born email found in 2026.

Q: How to contact Stephanie Born?

To contact Stephanie Born send an email to stephanie_born@merck.com. (updated on October 30, 2024)

Distinguished Scientist, Neuroscience Therapeutic Area Lead at Merck | West Point, Pennsylvania, United States

About Stephanie Born

Stephanie Born is a Senior Principal Scientist at Merck, where she plays a pivotal role in the nonclinical safety assessment of innovative pharmaceuticals, particularly in the fields of neuroscience and anti-infectives. With a robust background in toxicology and drug development, Stephanie is instrumental in shaping the strategic direction of nonclinical programs, ensuring that both early- and late-stage drug candidates meet the rigorous safety and efficacy standards required for regulatory submissions. Her dual responsibilities as a development team representative and study manager allow her to bridge the gap between scientific research and regulatory compliance, facilitating the smooth progression of neuroactive compounds and anti-infectives from the laboratory to clinical trials.

Stephanie's expertise extends to the preparation of complex regulatory documents for both US and international filings, where her meticulous attention to detail and comprehensive understanding of GLP (Good Laboratory Practice) guidelines are invaluable. She has successfully navigated the intricacies of nonclinical study design and reporting for a diverse range of therapeutic modalities, including small molecules, peptides, and monoclonal antibodies. Her proficiency in pharmacology and pharmaceutics further enhances her ability to assess the safety profiles of novel drug candidates, ensuring that they are not only effective but also safe for human use.

In addition to her technical skills, Stephanie is known for her collaborative approach, working closely with cross-functional teams to align nonclinical strategies with overall development goals. Her commitment to advancing pharmaceutical science and her passion for improving patient outcomes make her a key asset to Merck and the broader pharmaceutical industry. Through her leadership and expertise, Stephanie continues to contribute significantly to the development of groundbreaking therapies that address critical health challenges.

Stephanie Born Work